Study of CD56 Expression Patterns in Newly Diagnosed Patients with Hematologic Cancers and Healthy Controls

What this Trial Is About

Researchers are studying the expression pattern of CD56, a marker found on natural killer cells and other immune cells, in patients with hematologic malignancies. These blood cancers arise from bone marrow or lymphatic system cells and include diverse diseases such as leukemia, lymphoma, and multiple myeloma. While CD56 overexpression has been linked to certain conditions like acute myeloid leukemia, this study aims to explore its pattern across various hematologic cancers. The study involves detecting CD56 expression using a diagnostic test called flow cytometry. Participants include newly diagnosed patients with hematologic malignancies and control healthy individuals. This observational study will compare CD56 expression between these groups without administering any treatment. During the study, participants will undergo the CD56 detection test and provide samples for analysis. Researchers will measure how CD56 is expressed in different blood cancers over one year. The study also monitors participant health and gathers data to better understand the role of CD56 in these diseases. The total duration involves initial testing and follow-up evaluations as needed.

Aberrant Expression of CD56 in Patients With Hematologic Malignancies.